Posted by Michael Wonder on 28 Jan 2026
The European Commission extended the marketing authorisation for Vueway (gadopiclenol) in the European Union for use in paediatric patients under 2 years of age
27 January 2026 - Bracco Imaging announces that on 23 January 2026, the European Commission amended the Marketing Authorisation for Vueway (gadopiclenol) in the European Union, extending its approved indications to paediatric patients below 2 years of age.
The extension granted by the European Commission followed the relevant positive opinion of the CHMP of the EMA, and the recommendation sent by EMA to the European Commission.
